TRVI
Trevi Therapeutics, Inc.
TRVI
Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. (TRVI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Trevi Therapeutics leverages Haduvio's dual mechanism to target IPF-related chronic cough, with expansion plans into non-IPF ILD and refractory chronic cough. Haduvio's positive Phase II data in both
Trevi Therapeutics, Inc. (TRVI) Q2 2026 Earnings Call Transcript